Skip to content

CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load

CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01924052
Enrollment
40
Registered
2013-08-16
Start date
2013-06-30
Completion date
2013-08-31
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine Without Aura

Brief summary

The investigators hypothesized that migraine without patients with many genetic loci associated with migraine (high genetic load) would be more sensitive and get provoked more migraine attacks by calcitonin gene-related peptide (CGRP) compared to patients with few genetic loci associated with migraine (low genetic load).

Detailed description

Migraine is a very prevalent neurological disorder with a strong genetic factor. The common forms of migraine have a multifactorial and polygenic pattern of inheritance and genetics research is crucial for a deeper understanding of migraine mechanisms. Recently, 12 genetic loci have been identified to be associated with migraine with (MA) and without aura (MA) in four large genome-wide association studies (GWAS). The functional consequences of these genetic loci in humans are yet unknown. Calcitonin gene-related peptide (CGRP) is a neuropeptide which plays a crucial role in the pathophysiology of migraine and is present in migraine relevant structures. CGRP can induce migraine attacks in MO patients via an adenosine monophosphate (cAMP) dependent pathway and CGRP antagonism is efficient in the treatment of migraine attacks. Also, a recent study has showed that intracellular accumulation of cAMP is crucial for the induction of migraine attacks. However, CGRP does not cause migraine attacks in familial hemiplegic migraine (FHM), an autosomal dominant subtype of MA. The phenotype of the migraine inducing effects of CGRP might therefore be linked to some of the 12 genetic susceptibility loci that have been identified. One of the genetic loci (rs13208321) is located in a gene (FHL5) that is associated with the regulation of cAMP-responsive elements.

Interventions

DRUGCGRP

Calcitonin-gene-related-peptide (CGRP)

Sponsors

Danish Headache Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

\- Migraine without aura patients genotyped for the 12 newly idetified gene variants associated with migraine.

Exclusion criteria

* Other primary headache * A history of cerebrovascular disease and other CNS- disease * A history suggesting ischaemic heart disease * Serious somatic and mental disease * Hypo- or hypertension * Abuse of alcohol or medicine (opioid analgesics). * Pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frameDescription
CGRP induced migraine attacks in patients with high and low genetic loadChange from baseline in headache intensity at 12 hours after the start of infusion of CGRPThe difference in incidence of migraine-like attacks between patients with high genetic load and patients with low genetic load using verbal rating scale (VRS).

Secondary

MeasureTime frameDescription
CGRP induced migraine attacks in patients with high and low genetic loadChange from baseline in headache intensity at 12 hours after the start of infusion of CGRPThe difference in area under the curve (AUC) for headache intensity scores (0-12 hours)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026